Five-aminosalicylic Acid: an Update for the Reappraisal of an Old Drug

Overview

Journal Gastroenterol Res Pract

Publisher Wiley

Specialty Gastroenterology

Date 2015 Feb 17

PMID 25685145

Citations 17

Authors

Cristiana Perrotta

Paolo Pellegrino

Eliana Moroni

Clara De Palma

Davide Cervia

Piergiorgio Danelli

Emilio Clementi

Affiliations

Soon will be listed here.

Abstract

Inflammatory bowel disease (IBD) comprises several conditions with chronic or recurring immune response and inflammation of the gastrointestinal apparatus, of which ulcerative colitis and Crohn's disease are the commonest forms. This disease has a significant prevalence and it is of an unknown aethiology. Five-aminosalicylic acid (5-ASA) and its derivatives are among the oldest drugs approved for the treatment of the IBD. In this review we reapprise aspects of 5-ASA mechanism of action, safety, and efficacy that in our opinion make it a valuable drug that can be fruitfully tailored in personalised treatments as a therapeutic option alongside other immune-modifying agents.

Citing Articles

[Efficient treatment of mild Crohn's disease and mild ulcerative colitis].

Rogler G Inn Med (Heidelb). 2024; 66(1):15-21.

PMID: 39715834 PMC: 11761793. DOI: 10.1007/s00108-024-01840-x.

Harnessing a Safe Novel Lipid Nanoparticle: Targeted Oral Delivery to Colonic Epithelial and Macrophage Cells in a Colitis Mouse Model.

Mow R, Kuczma M, Shi X, Mani S, Merlin D, Yang C Nanomaterials (Basel). 2024; 14(22).

PMID: 39591041 PMC: 11597058. DOI: 10.3390/nano14221800.

Oral colon-targeted pH-responsive polymeric nanoparticles loading naringin for enhanced ulcerative colitis therapy.

Fan S, Zhao Y, Yao Y, Shen X, Chai X, Li J J Transl Med. 2024; 22(1):878.

PMID: 39350164 PMC: 11440766. DOI: 10.1186/s12967-024-05662-1.

Oral delivery of pH-sensitive nanoparticles loaded Celastrol targeting the inflammatory colons to treat ulcerative colitis.

Zhao Y, Yao Y, Fan S, Shen X, Chai X, Li Z J Tissue Eng. 2024; 15:20417314241265892.

PMID: 39130681 PMC: 11316965. DOI: 10.1177/20417314241265892.

The aminosalicylate - folate connection.

London R Drug Metab Rev. 2024; 56(1):80-96.

PMID: 38230664 PMC: 11305456. DOI: 10.1080/03602532.2024.2303507.

References

Merceron O, Bailly C, Khalil A, Pontnau F, Hammoudi N, Dorent R . Mesalamine-induced myocarditis. Cardiol Res Pract. 2010; 2010. PMC: 2943131. DOI: 10.4061/2010/930190. View

Parenti S, Ferrarini F, Zini R, Montanari M, Losi L, Canovi B . Mesalazine inhibits the beta-catenin signalling pathway acting through the upregulation of mu-protocadherin gene in colo-rectal cancer cells. Aliment Pharmacol Ther. 2009; 31(1):108-19. DOI: 10.1111/j.1365-2036.2009.04149.x. View

Ford A, Khan K, Sandborn W, Kane S, Moayyedi P . Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011; 106(12):2070-7. DOI: 10.1038/ajg.2011.296. View

Abraham A, Karakurum A . Acute respiratory failure secondary to mesalamine-induced interstitial pneumonitis. BMJ Case Rep. 2013; 2013. PMC: 3761449. DOI: 10.1136/bcr-2013-009834. View

Lankisch P, Droge M, Gottesleben F . Drug induced acute pancreatitis: incidence and severity. Gut. 1995; 37(4):565-7. PMC: 1382911. DOI: 10.1136/gut.37.4.565. View

Managlia E, Katzman R, Brown J, Barrett T . Antioxidant properties of mesalamine in colitis inhibit phosphoinositide 3-kinase signaling in progenitor cells. Inflamm Bowel Dis. 2013; 19(10):2051-60. PMC: 8754500. DOI: 10.1097/MIB.0b013e318297d741. View

Zallot C, Billioud V, Frimat L, Faure P, Peyrin-Biroulet L . 5-Aminosalicylates and renal function monitoring in inflammatory bowel disease: a nationwide survey. J Crohns Colitis. 2012; 7(7):551-5. DOI: 10.1016/j.crohns.2012.08.013. View

Bos C, Diks S, Hardwick J, Walburg K, Peppelenbosch M, Richel D . Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity. Carcinogenesis. 2006; 27(12):2371-82. DOI: 10.1093/carcin/bgl071. View

Sabatini T, Filippini A, Nicosia F, Preti S, Bertoli M . Recurrence of myocarditis after mesalazine treatment for ulcerative colitis: a case report. Inflamm Bowel Dis. 2012; 19(3):E46-8. DOI: 10.1002/ibd.22985. View

10.

Sharon P, Ligumsky M, Rachmilewitz D, ZOR U . Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology. 1978; 75(4):638-40. View

11.

Feagan B, MacDonald J . Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012; 10:CD000544. DOI: 10.1002/14651858.CD000544.pub3. View

12.

COLLIER H, Francis A, Saeed S . Inhibition of prostaglandin biosynthesis by sulphasalazine and its metabolites. Prostaglandins. 1976; 11(2):219-25. DOI: 10.1016/0090-6980(76)90145-3. View

13.

Zhao L, Li J, Yu T, Chen G, Yuan Y, Chen Q . 5-Aminosalicylates reduce the risk of colorectal neoplasia in patients with ulcerative colitis: an updated meta-analysis. PLoS One. 2014; 9(4):e94208. PMC: 3978022. DOI: 10.1371/journal.pone.0094208. View

14.

Szanto A, Nagy L . The many faces of PPARgamma: anti-inflammatory by any means?. Immunobiology. 2008; 213(9-10):789-803. DOI: 10.1016/j.imbio.2008.07.015. View

15.

Koonce S, Asbun H, Stauffer J . Management of disconnected left pancreatic remnant after necrotizing pancreatitis. Am Surg. 2014; 80(5):E137-8. View

16.

Leff M, Fretland A, Doll M, Hein D . Novel human N-acetyltransferase 2 alleles that differ in mechanism for slow acetylator phenotype. J Biol Chem. 1999; 274(49):34519-22. DOI: 10.1074/jbc.274.49.34519. View

17.

Ford A, Kane S, Khan K, Achkar J, Talley N, Marshall J . Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. Am J Gastroenterol. 2011; 106(4):617-29. DOI: 10.1038/ajg.2011.71. View

18.

World M, Stevens P, Ashton M, Rainford D . Mesalazine-associated interstitial nephritis. Nephrol Dial Transplant. 1996; 11(4):614-21. DOI: 10.1093/oxfordjournals.ndt.a027349. View

19.

Stolfi C, Pellegrini R, Franze E, Pallone F, Monteleone G . Molecular basis of the potential of mesalazine to prevent colorectal cancer. World J Gastroenterol. 2008; 14(28):4434-9. PMC: 2731267. DOI: 10.3748/wjg.14.4434. View

20.

Lin H, Probst-Hensch N, Hughes N, Sakamoto G, Louie A, Kau I . Variants of N-acetyltransferase NAT1 and a case-control study of colorectal adenomas. Pharmacogenetics. 1998; 8(3):269-81. DOI: 10.1097/00008571-199806000-00009. View